WallStreetZenWallStreetZen

NASDAQ: ARCT
Arcturus Therapeutics Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ARCT

Based on 5 analysts offering 12 month price targets for Arcturus Therapeutics Holdings Inc

Min Forecast
$8.00+33.33%
Avg Forecast
$20.60+243.33%
Max Forecast
$27.00+350%

Should I buy or sell ARCT stock?

Based on 5 analysts offering ratings for Arcturus Therapeutics Holdings Inc.

Strong Buy
Strong Buy
4 analysts 80%
Buy
0 analysts 0%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ARCT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ARCT as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their ARCT stock forecasts and price targets.

ARCT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-02
lockedlocked$00.00+00.00%2026-03-18
lockedlocked$00.00+00.00%2026-03-05
lockedlocked$00.00+00.00%2026-03-04
lockedlocked$00.00+00.00%2026-03-04

1 of 1

Forecast return on equity

Is ARCT forecast to generate an efficient return?

Company
-30.88%
Industry
86.97%
Market
179.63%
ARCT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ARCT forecast to generate an efficient return on assets?

Company
-24.08%
Industry
26.33%
ARCT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ARCT earnings per share forecast

What is ARCT's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$3.90
Avg 2 year Forecast
-$4.03
Avg 3 year Forecast
-$3.56

ARCT revenue forecast

What is ARCT's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$23.6M-56.83%
Avg 2 year Forecast
$36.0M-34.27%
Avg 3 year Forecast
$51.3M-6.15%
ARCT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ARCT revenue growth forecast

How is ARCT forecast to perform vs Biotechnology companies and vs the US market?

Company
-2.46%
Industry
34.56%
Market
13.83%
ARCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARCT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARCT$6.00$20.60+243.33%Strong Buy
TNXP$10.67$24.00+125.04%Strong Buy
ADAG$3.63$10.00+175.48%Strong Buy
ALEC$1.51$6.00+297.35%Strong Buy
CRBP$8.92$39.00+337.22%Strong Buy
View Top Biotech Stocks

Arcturus Therapeutics Holdings Stock Forecast FAQ

Is Arcturus Therapeutics Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ARCT) stock is to Strong Buy ARCT stock.

Out of 5 analysts, 4 (80%) are recommending ARCT as a Strong Buy, 0 (0%) are recommending ARCT as a Buy, 1 (20%) are recommending ARCT as a Hold, 0 (0%) are recommending ARCT as a Sell, and 0 (0%) are recommending ARCT as a Strong Sell.

If you're new to stock investing, here's how to buy Arcturus Therapeutics Holdings stock.

What is ARCT's earnings growth forecast for 2026-2028?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.27%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.72%.

Arcturus Therapeutics Holdings's earnings in 2026 is -$78,671,000.On average, 14 Wall Street analysts forecast ARCT's earnings for 2026 to be -$110,949,450, with the lowest ARCT earnings forecast at -$156,264,349, and the highest ARCT earnings forecast at -$38,499,047. On average, 14 Wall Street analysts forecast ARCT's earnings for 2027 to be -$114,536,441, with the lowest ARCT earnings forecast at -$147,072,328, and the highest ARCT earnings forecast at -$75,505,883.

In 2028, ARCT is forecast to generate -$101,083,803 in earnings, with the lowest earnings forecast at -$140,665,768 and the highest earnings forecast at -$60,285,329.

What is ARCT's revenue growth forecast for 2026-2028?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of -2.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.83%.

Arcturus Therapeutics Holdings's revenue in 2026 is $54,709,000.On average, 14 Wall Street analysts forecast ARCT's revenue for 2026 to be $671,352,890, with the lowest ARCT revenue forecast at $187,563,832, and the highest ARCT revenue forecast at $3,062,017,223. On average, 14 Wall Street analysts forecast ARCT's revenue for 2027 to be $1,022,065,138, with the lowest ARCT revenue forecast at $228,407,782, and the highest ARCT revenue forecast at $3,814,091,629.

In 2028, ARCT is forecast to generate $1,459,382,478 in revenue, with the lowest revenue forecast at $228,407,782 and the highest revenue forecast at $3,188,784,111.

What is ARCT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ARCT) forecast ROA is -24.08%, which is lower than the forecast US Biotechnology industry average of 26.33%.

What is ARCT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ARCT price target, the average ARCT price target is $20.60, with the highest ARCT stock price forecast at $27.00 and the lowest ARCT stock price forecast at $8.00.

On average, Wall Street analysts predict that Arcturus Therapeutics Holdings's share price could reach $20.60 by Jul 2, 2027. The average Arcturus Therapeutics Holdings stock price prediction forecasts a potential upside of 243.33% from the current ARCT share price of $6.00.

What is ARCT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings's current Earnings Per Share (EPS) is -$2.83. On average, analysts forecast that ARCT's EPS will be -$3.90 for 2026, with the lowest EPS forecast at -$5.50, and the highest EPS forecast at -$1.35. On average, analysts forecast that ARCT's EPS will be -$4.03 for 2027, with the lowest EPS forecast at -$5.17, and the highest EPS forecast at -$2.66. In 2028, ARCT's EPS is forecast to hit -$3.56 (min: -$4.95, max: -$2.12).

What is ARCT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ARCT) forecast ROE is -30.88%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.